### **Poster #:** W4018

# A Novel In Silico Screening Protocol For The Selection Of Optimized **Precipitation Inhibitor Systems For Supersaturable Formulations** Daniel Price<sup>1,2</sup> Christoph Saal<sup>1</sup>, Anita Nair<sup>1</sup>, Prof. Jennifer Dressman<sup>2</sup> <sup>1</sup>Merck KGaA, Darmstadt, Germany; <sup>2</sup>Frankfurt Goethe University, Frankfurt, Germany


Daniel-joseph.price@merckgroup.com

## PURPOSE

- Supersaturable formulations represent a viable option for improving bioavailability of poorly soluble active pharmaceutical ingredients (APIs).
- Given the metastable nature of the supersaturated state, precipitation inhibitors (PIs) are required to sustain API in solution for physiologically relevant time scales.
- PI selection is currently very 'trial-and-error' based
- This study aimed to develop a novel *in silico* screening protocol for precipitation inhibitor systems, allowing for a more scientific and efficient selection process


## **METHODS**

- Glibenclamide Loaded Silica (GBLSi), prepared using the solvent impregnation method, was used as a model supersaturable formulation.
- Screening for theoretical enthalpy of interaction between glibenclamide and 52 precipitation inhibitors was carried out using the COSMOquick® software<sup>1</sup>
- The enthalpy 'rank-order' was used as a parameter for the selection of a range of precipitation inhibitors, which were then physically blended with the formulation (API : PI, 1 : 3)
- A small-scale single-medium FaSSIF (pH 6.5) dissolution and biorelevant transfer dissolution (SGF, pH 2.0 $\rightarrow$ FaSSIF, pH 6.5) was performed on formulations at 37°C to assess the correlation between the COSMOquick® prediction and the actual dissolution performance. Precipitation residues from dissolution experiments were subjected to PXRD for solid-state characterization.
- Physical mixtures of glibenclamide with selected polymers were analyzed for their dissolution characteristics to rule out any innate solubility enhancement effects only by the polymer.



inhibitor selection?

**COSMOlogic** Predicting Solutions



**COSMOQUICK**®

### **RESULTS AND DISCUSSIONS**

### **COSMOQUICK® SCREEN**


- Eduragit E100 (EU) was predicted to have the most significant enthalpy of interaction (Figure 1).
- The polymers: HPMCAS, HPMC and PVP, commonly used in the trial and error approach, were predicted to interact less strongly.
- EU, Pluronic (PLR), PEG, HPMCAS, PVP and HPMC were selected for the formulations.

### SINGLE-MEDIUM FASSIF DISSOLUTION

- GBLSi generated significant supersaturation (*ca.* 15fold), after which precipitation and re-crystallization occurred rapidly (Figures 2 and 3).
- EU, PLR and HPMCAS act as successful 'parachutes' with varying degrees of success (Figures 2 and 3).
- The AUCs of the curves correlated well with the rankorder predicted by COSMOquick® except for PEG (Table 1). The PI effect of PEG is likely to be dependent on bound water which is not considered in COSMOquick® predictions.
- The most effective PI system, EU, showed no crystallinity in the post-dissolution residues, compared to the other formulation residues, which showed some partial-crystallinity (Figure 4).
- Furthermore, the EU formulation resulted in a 20-fold sustained supersaturation in a biorelevant transfer model (*not shown*) compared to only a 2-fold effect for HPMCAS.
- Physical mixtures of API and polymers showed no enhanced dissolution (*not shown*)- supporting the PI mechanism, as opposed to solubility enhancement.

### CONCLUSIONS

- ✓ Developed an novel PI screening protocol utilising the *in silico* software **COSMOquick**®
- ✓ The PIs selected for the model formulations, based on the *in silico* predictions, showed good correlation with their actual dissolution performance, with the predicted PIs significantly outperforming those commonly used in trial-and-error PI selection
- ✓ The developed protocol has applicability to alternative supersaturable formulations



References 1) Abramov, YA. et al. Rational Co-former or Solvent Selection for Pharmaceutical Co-crystallization or Desolvation. Journal of Pharmaceutical Sciences. 2012; **101**(10): 3687-3697







